[1] HOSSAIN MA, COSTANZO E, COSENTINO J, et al. Contrast-induced nephropathy: Pathophysiology, risk factors, and prevention[J]. Saudi J Kidney Dis Transpl, 2018, 29(1): 1. doi: 10.4103/1319-2442.225199
[2] KHATAMI MR, NIKRAVAN N, SALARI-FAR M, et al. A comparison of definitions of contrast-induced nephropathy in patients with normal serum creatinine[J]. Saudi J Kidney Dis Transpl, 2016, 27(1): 94. doi: 10.4103/1319-2442.174086
[3] 陈文, 裴源源, 朱继红. 急性心肌梗死行介入术发生造影剂肾病的危险因素[J]. 中华急诊医学杂志, 2018, 27(7): 752. doi: 10.3760/cma.j.issn.1671-0282.2018.07.009
[4] MURATOGLU M, KAVALCI C, KILICLI E, et al. Serum neutrophil gelatinase-associated lipocalin levels in early detection of contrast-induced nephropathy[J]. Clin Invest Med, 2016, 39(3): 88. doi: 10.25011/cim.v39i3.26797
[5] AKDENIZ D, CELIK HT, KAZANCI F, et al. Is kidney injury molecule 1 a valuable tool for the early diagnosis of contrast-induced nephropathy[J]. J Investig Med, 2015, 63(8): 930. doi: 10.1097/JIM.0000000000000243
[6] 马常乐, 汤成春, 秦雨晗, 等. 术前尿微量白蛋白/尿肌酐比值与造影剂肾病的相关性研究[J]. 东南大学学报(医学版), 2019, 38(1): 174. doi: 10.3969/j.issn.1671-6264.2019.01.036
[7] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10): 766.
[8] STACUL F, VAN DER MOLEN AJ, REIMER P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines[J]. Eur Radiol, 2011, 21(12): 2527. doi: 10.1007/s00330-011-2225-0
[9] 桑文涛, 杨可慧, 李笑, 等. 造影剂肾病早期预防的研究进展[J]. 中华危重病急救医学, 2019, 31(9): 1174. doi: 10.3760/cma.j.issn.2095-4352.2019.09.025
[10] RUDNICK MR, LEONBERG-YOO AK, LITT HI, et al. The controversy of contrast-induced nephropathy with intravenous contrast: what is the risk?[J]. Am J Kidney Dis, 2020, 75(1): 105. doi: 10.1053/j.ajkd.2019.05.022
[11] 李永旺, 杨同肖, 侯丽萍, 等. CHADACv评分与肾损伤分子-1检测对行经皮冠状动脉介入治疗冠心病患者造影剂肾病的评估价值[J]. 中国心血管病研究, 2019, 17(11): 994. doi: 10.3969/j.issn.1672-5301.2019.11.008
[12] 张会芬, 杨宏秀, 刘丽, 等. 血清中性粒细胞明胶酶相关脂质运载蛋白, 胱抑素C及尿白蛋白肌酐比值, N-乙酰-β-D-氨基葡萄糖苷酶检测在早期糖尿病肾脏疾病中的应用价值[J]. 中国糖尿病杂志, 2018, 26(4): 309. doi: 10.3969/j.issn.1006-6187.2018.04.009
[13] 姜洁, 吕菁君, 叶璐, 等. 可溶性血栓调节蛋白及中性粒细胞明胶酶相关脂质运载蛋白早期预测脓毒症相关急性肾损伤的临床研究[J]. 中华急诊医学杂志, 2020, 29(4): 533. doi: 10.3760/cma.j.issn.1671-0282.2020022.007-1
[14] SEIBERT FS, SITZ M, PASSFALL J, et al. Prognostic value of urinary calprotectin, NGAL and KIM-1 in chronic kidney disease[J]. Kidney Blood Press Res, 2018, 43(4): 1255. doi: 10.1159/000492407
[15] 李秀珍, 谭晓, 高逸冰, 等. 血清中性粒细胞明胶酶相关脂质运载蛋白对对比剂肾病的早期预测价值[J]. 中华老年多器官疾病杂志, 2019, 18(3): 210.
[16] ZHU H, QIAN YY. Serum neutrophil gelatinase-associated lipocalin and cystatin C are diagnostic markers of renal dysfunction in older patients with coronary artery disease[J]. J Int Med Res, 2018, 46(6): 2177. doi: 10.1177/0300060517748842
[17] TANASE DM, GOSAV EM, RADU S, et al. The predictive role of the biomarker kidney molecule-1(KIM-1) in acute kidney injury(AKI) cisplatin-induced nephrotoxicity[J]. Int J Mol Sci, 2019, 20(20): 5238. doi: 10.3390/ijms20205238
[18] SHANG W, WANG Z. The update of NGAL in acute kidney injury[J]. Curr Protein Pept Sci, 2017, 18(12): 1211.